Safety and Efficacy of SUM-191 for Patients With Bacterial Conjunctivitis

This is a seamless Phase I/II, randomized, double-masked, placebo-controlled, multicenter trial to evaluate single and multiple-dose safety and tolerability of SUM-191 in healthy participants in Parts 1 (SAD) and 2 (MAD) ; and multiple-dose efficacy and safety of SUM-191 in participants with bacterial conjunctivitis in Part 3.

NCT Number	NCT07565103
Lead Sponsor	Senju USA, Inc.
Conditions	Bacterial Conjunctivitis
Enrollment	426 participants
Start Date	2026-06-25
Primary Completion	2028-08-15 (estimated)
Study Completion	2028-08-15 (estimated)
Updated on ClinicalTrials.gov	2026-06-30